Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study

• DOI: 10.1111/jdv.17094
• Publication Date: 2020-12-18T11:33:37Z
• Authors: C. Patruno; M. Napolitano; G. Argenziano; K. Peris; M. Ortoncelli; G. Girolomoni; A. Offidani; S.M. Ferrucci; G.F. Amoruso; M. Rossi; L. Stingeni; G. Malara; T. Grieco; C. Foti; M. Gattoni; C. Loi; M. Iannone; M. Talamonti; G. Stinco; F. Rongioletti; P.D. Pigatto; A. Cristaudo; E. Nettis; M. Corazza; F. Guarneri; P. Amerio; M. Esposito; A. Belloni Fortina; C. Potenza; G. Fabbrocini
• Keywords: Dupilumab; Prurigo nodularis

Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects traditional anti-inflammatory drugs and comorbidities often found this age group. Furthermore, efficacy safety innovative such as dupilumab are not yet well known.A multicentre retrospective, observational, real-life study on was conducted a group patients aged ≥65 years affected by severe AD. Their main clinical features were also examined.Data with (EASI ≥24) AD treated at label dosage for 16 weeks retrospectively collected. outcome assessed comparing objective (EASI) subjective (P-NRS, S-NRS DLQI) scores baseline after treatment.Two hundred seventy-six enrolled study. They represented 11.37% all Flexural eczema most frequent phenotype, followed prurigo nodularis. The coexistence more than one phenotype 63/276 (22.82%) subjects. Data 16-week treatment available 253 (91.67%) patients. Efficacy demonstrated significant reduction scores. No statistically difference regarding when compared our 18-64 years, over same period. only 18 (6.52%) discontinued drug inefficacy. Sixty-one (22.51%) reported adverse events, conjunctivitis flushing being frequent. One (0.36%) patient an event.Therapy led improvement period, good profile. Therefore, could considered efficacious safe elderly.